SE378110B - - Google Patents

Info

Publication number
SE378110B
SE378110B SE7206645A SE664572A SE378110B SE 378110 B SE378110 B SE 378110B SE 7206645 A SE7206645 A SE 7206645A SE 664572 A SE664572 A SE 664572A SE 378110 B SE378110 B SE 378110B
Authority
SE
Sweden
Application number
SE7206645A
Inventor
R L Brattsand
K G Claeson
Af Ekenstam B Thuresson
B A Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Priority to SE7206645A priority Critical patent/SE378110B/xx
Priority to IL42154A priority patent/IL42154A/en
Priority to ZA732956A priority patent/ZA732956B/xx
Priority to AU55252/73A priority patent/AU478324B2/en
Priority to GB2219573A priority patent/GB1428416A/en
Priority to DE2323216A priority patent/DE2323216C3/de
Priority to CY1012A priority patent/CY1012A/xx
Priority to US359913A priority patent/US3928326A/en
Priority to FI731543A priority patent/FI50711C/fi
Priority to DK277073A priority patent/DK133249C/da
Priority to CA171,781A priority patent/CA1003402A/en
Priority to FR7318126A priority patent/FR2185406B1/fr
Priority to SU1918554A priority patent/SU468408A3/ru
Priority to BE131271A priority patent/BE799728A/xx
Priority to NLAANVRAGE7306979,A priority patent/NL175917C/xx
Priority to JP5623473A priority patent/JPS547794B2/ja
Publication of SE378110B publication Critical patent/SE378110B/xx
Priority to US05/629,493 priority patent/US3996359A/en
Priority to US05/629,390 priority patent/US3992534A/en
Priority to KE2969A priority patent/KE2969A/xx
Priority to HK490/79A priority patent/HK49079A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SE7206645A 1972-05-19 1972-05-19 SE378110B (cg-RX-API-DMAC10.html)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (cg-RX-API-DMAC10.html) 1972-05-19 1972-05-19
IL42154A IL42154A (en) 1972-05-19 1973-05-01 Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby
ZA732956A ZA732956B (en) 1972-05-19 1973-05-01 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
AU55252/73A AU478324B2 (en) 1972-05-19 1973-05-04 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
GB2219573A GB1428416A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby
DE2323216A DE2323216C3 (de) 1972-05-19 1973-05-09 Verfahren zur Auftrennung von Stereoisomerengemischen von Pregna-1,4dien-11 -ol-33-dionen
CY1012A CY1012A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby
US359913A US3928326A (en) 1972-05-19 1973-05-14 Process for the separation of stereoisomeric mixtures into their components and components obtained hereby
FI731543A FI50711C (fi) 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.
DK277073A DK133249C (da) 1972-05-19 1973-05-17 Fremgangsmade til opspaltning af stereoisomerblandinger af 16alfa,17alfa-alkylidendioxypregnan-11beta,21-diol-3,20-dioner
CA171,781A CA1003402A (en) 1972-05-19 1973-05-18 Process for the separation of steroisomeric mixtures into their components and components obtained hereby
FR7318126A FR2185406B1 (cg-RX-API-DMAC10.html) 1972-05-19 1973-05-18
SU1918554A SU468408A3 (ru) 1972-05-19 1973-05-18 Способ разделени стереоизомерных смесей
BE131271A BE799728A (fr) 1972-05-19 1973-05-18 Procede pour la separation de steredoisomeres de certains steroides
NLAANVRAGE7306979,A NL175917C (nl) 1972-05-19 1973-05-18 Werkwijze voor het splitsen van isomere mengsels van steroiden, werkwijze voor het bereiden van een farmaceutisch preparaat en aldus verkregen gevormd farmaceutisch preparaat.
JP5623473A JPS547794B2 (cg-RX-API-DMAC10.html) 1972-05-19 1973-05-19
US05/629,493 US3996359A (en) 1972-05-19 1975-11-06 Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
US05/629,390 US3992534A (en) 1972-05-19 1975-11-06 Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
KE2969A KE2969A (en) 1972-05-19 1979-06-20 A process for the separation of sterioisomeric mixtures of steroid acetalsinto, their components and components obtained thereby
HK490/79A HK49079A (en) 1972-05-19 1979-07-19 A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (cg-RX-API-DMAC10.html) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
SE378110B true SE378110B (cg-RX-API-DMAC10.html) 1975-08-18

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7206645A SE378110B (cg-RX-API-DMAC10.html) 1972-05-19 1972-05-19

Country Status (17)

Country Link
US (1) US3928326A (cg-RX-API-DMAC10.html)
JP (1) JPS547794B2 (cg-RX-API-DMAC10.html)
BE (1) BE799728A (cg-RX-API-DMAC10.html)
CA (1) CA1003402A (cg-RX-API-DMAC10.html)
CY (1) CY1012A (cg-RX-API-DMAC10.html)
DE (1) DE2323216C3 (cg-RX-API-DMAC10.html)
DK (1) DK133249C (cg-RX-API-DMAC10.html)
FI (1) FI50711C (cg-RX-API-DMAC10.html)
FR (1) FR2185406B1 (cg-RX-API-DMAC10.html)
GB (1) GB1428416A (cg-RX-API-DMAC10.html)
HK (1) HK49079A (cg-RX-API-DMAC10.html)
IL (1) IL42154A (cg-RX-API-DMAC10.html)
KE (1) KE2969A (cg-RX-API-DMAC10.html)
NL (1) NL175917C (cg-RX-API-DMAC10.html)
SE (1) SE378110B (cg-RX-API-DMAC10.html)
SU (1) SU468408A3 (cg-RX-API-DMAC10.html)
ZA (1) ZA732956B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SK87295A3 (en) * 1993-01-08 1996-04-03 Astra Ab Novel colon or ileum-specific steroid derivatives
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN101616901A (zh) * 2006-09-22 2009-12-30 兰贝克赛实验室有限公司 Iv型磷酸二酯酶的抑制剂
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674084C (en) 2006-12-26 2013-05-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
PL2124944T3 (pl) 2007-03-14 2012-08-31 Sun Pharmaceutical Ind Ltd Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011029547A2 (en) * 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2534145A4 (en) 2010-02-08 2013-09-11 Kinagen Inc THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN103282497B (zh) 2010-08-17 2018-07-10 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
MX365393B (es) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
NZ704799A (en) 2012-08-24 2018-06-29 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 癌を処置するための組成物および方法
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP4659809A2 (en) 2016-11-08 2025-12-10 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN112004557B (zh) 2018-01-08 2024-07-30 里珍纳龙药品有限公司 类固醇类化合物及其抗体偶联物
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
KR20210046009A (ko) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 Prmt5 억제제
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
PE20251547A1 (es) 2022-10-25 2025-06-05 Merck Sharp And Dohme Llc Enlazadores-cargas utiles de adc derivados de exatecan, composiciones farmaceuticas, y usos de los mismos
EP4633681A1 (en) 2022-12-14 2025-10-22 Merck Sharp & Dohme LLC Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Also Published As

Publication number Publication date
IL42154A0 (en) 1973-07-30
BE799728A (fr) 1973-09-17
JPS547794B2 (cg-RX-API-DMAC10.html) 1979-04-10
NL7306979A (cg-RX-API-DMAC10.html) 1973-11-21
FI50711C (fi) 1976-06-10
DE2323216B2 (de) 1977-11-03
JPS4941379A (cg-RX-API-DMAC10.html) 1974-04-18
ZA732956B (en) 1974-04-24
KE2969A (en) 1979-07-20
DE2323216C3 (de) 1978-06-22
CA1003402A (en) 1977-01-11
DE2323216A1 (de) 1973-11-29
IL42154A (en) 1976-12-31
CY1012A (en) 1979-11-23
FR2185406A1 (cg-RX-API-DMAC10.html) 1974-01-04
DK133249C (da) 1976-09-13
SU468408A3 (ru) 1975-04-25
FI50711B (cg-RX-API-DMAC10.html) 1976-03-01
HK49079A (en) 1979-07-27
FR2185406B1 (cg-RX-API-DMAC10.html) 1976-12-31
DK133249B (da) 1976-04-12
NL175917C (nl) 1985-01-16
US3928326A (en) 1975-12-23
GB1428416A (en) 1976-03-17
AU5525273A (en) 1974-11-07
NL175917B (nl) 1984-08-16

Similar Documents

Publication Publication Date Title
FR2185406B1 (cg-RX-API-DMAC10.html)
JPS4917524A (cg-RX-API-DMAC10.html)
CH564089A5 (cg-RX-API-DMAC10.html)
BG19449A1 (cg-RX-API-DMAC10.html)
BG18077A1 (cg-RX-API-DMAC10.html)
BG18152A1 (cg-RX-API-DMAC10.html)
BG18347A1 (cg-RX-API-DMAC10.html)
BG18354A1 (cg-RX-API-DMAC10.html)
BG18395A1 (cg-RX-API-DMAC10.html)
BG18440A1 (cg-RX-API-DMAC10.html)
BG18477A1 (cg-RX-API-DMAC10.html)
CH566898A5 (cg-RX-API-DMAC10.html)
CH566510A5 (cg-RX-API-DMAC10.html)
CH545685A (cg-RX-API-DMAC10.html)
CH560019A5 (cg-RX-API-DMAC10.html)
CH560434A5 (cg-RX-API-DMAC10.html)
CH561007A5 (cg-RX-API-DMAC10.html)
CH561296A5 (cg-RX-API-DMAC10.html)
CH561361A5 (cg-RX-API-DMAC10.html)
CH562235A5 (cg-RX-API-DMAC10.html)
CH562278A5 (cg-RX-API-DMAC10.html)
CH563023A5 (cg-RX-API-DMAC10.html)
CH563249A5 (cg-RX-API-DMAC10.html)
CH563951A5 (cg-RX-API-DMAC10.html)
BG18070A1 (cg-RX-API-DMAC10.html)